Last reviewed · How we verify
NCT04617704
BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
EARLY_PHASE1 trial testing GC012F injection in Multiple Myeloma in 15 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Shanghai Changzheng Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 December 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 1 February 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- GC012F injection — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Shanghai Changzheng Hospital
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm, open label, multi-center prospective study to explory the safety and efficacy of GC012F CAR-T cells in patient diagnosed with high-risk chromosomal abnormalities BCMA+ multiple myeloma(MM).
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2 -
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255 -
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
Qin H, Zhou Z, Shi R, Mai Y, et al · · 2025 · cited 15× · PMID 40483473 · DOI 10.1186/s13045-025-01701-6 -
Updates on CAR T cell therapy in multiple myeloma.
Nasiri F, Asaadi Y, Mirzadeh F, Abdolahi S, et al · · 2024 · cited 10× · PMID 39261906 · DOI 10.1186/s40364-024-00634-5 -
Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.
Hasanali ZS, Razzo B, Susanibar-Adaniya SP, Garfall AL, et al · · 2024 · cited 3× · PMID 38158242 · DOI 10.1016/j.hoc.2023.12.004
Verify or expand the search:
- PubMed search for NCT04617704
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GC012F injection
Trials testing the same drug.
- NCT07072884 — GC012F in Patients With Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07058298 — GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) · EARLY_PHASE1 · recruiting
- NCT06759948 — An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis · Phase 1 · not yet recruiting
- NCT06419166 — An Exploratory Clinical Study of GC012F Injection for Refractory gMG · EARLY_PHASE1 · withdrawn
- NCT05846347 — Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus · Phase 1 · unknown
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Shanghai Changzheng Hospital trials
Trials by the same sponsor.
- NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
- NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
- NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
- NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04617704 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
- Last refreshed: 22 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04617704.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing